Cornercap Investment Counsel Inc. Buys New Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Cornercap Investment Counsel Inc. purchased a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 22,209 shares of the company’s stock, valued at approximately $191,000. Cornercap Investment Counsel Inc. owned approximately 0.05% of Mineralys Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Samsara BioCapital LLC bought a new position in Mineralys Therapeutics in the first quarter valued at $70,773,000. Braidwell LP increased its position in shares of Mineralys Therapeutics by 267.8% during the 3rd quarter. Braidwell LP now owns 2,023,900 shares of the company’s stock valued at $19,247,000 after purchasing an additional 1,473,600 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Mineralys Therapeutics during the 1st quarter valued at about $11,740,000. CHI Advisors LLC bought a new stake in Mineralys Therapeutics in the 3rd quarter worth approximately $5,405,000. Finally, FMR LLC boosted its stake in Mineralys Therapeutics by 62.6% in the third quarter. FMR LLC now owns 1,188,653 shares of the company’s stock worth $11,304,000 after buying an additional 457,815 shares in the last quarter. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Trading Down 0.6 %

NASDAQ:MLYS opened at $12.00 on Thursday. The company has a fifty day moving average of $13.78 and a 200 day moving average of $10.31. Mineralys Therapeutics, Inc. has a 52 week low of $5.85 and a 52 week high of $17.70.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.24. On average, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -2.44 EPS for the current year.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc acquired 555,555 shares of the company’s stock in a transaction on Monday, February 12th. The stock was acquired at an average price of $13.50 per share, for a total transaction of $7,499,992.50. Following the acquisition, the insider now owns 5,074,916 shares in the company, valued at approximately $68,511,366. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Analyst Ratings Changes

Several research analysts have commented on MLYS shares. The Goldman Sachs Group assumed coverage on shares of Mineralys Therapeutics in a research note on Tuesday, April 2nd. They set a “buy” rating and a $30.00 price target on the stock. Lifesci Capital reaffirmed an “outperform” rating on shares of Mineralys Therapeutics in a report on Tuesday, March 26th.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.